


Probing the Aglycon Promiscuity of an Engineered Glycosyltransferase**

Richard W. Gantt, Randal D. Goff, Gavin J. Williams, and Jon S. Thorson*

Sugars appended to pharmaceutically important natural products influence their key pharmacological properties and/or molecular mechanisms of action.^[1] However, studies designed to systematically understand or exploit the role of carbohydrates in drug discovery are often limited by the availability of practical synthetic and biosynthetic tools.^[2] Among the contemporary options to address this limitation,^[3–4] chemoenzymatic glycorandomization utilizes a set of flexible enzymes consisting of an anomeric kinase, sugar-1-phosphate nucleotidyltransferase, and natural product glycosyltransferase (GT).^[4–6] While chemoenzymatic glycorandomization has been successfully applied to alter the natural sugar moieties of numerous natural products,^[4–8] the process remains primarily restricted by enzyme specificity and availability of suitable GTs for the target of interest. Thus, although there is precedent for improving non-glycosylated therapeutics by glycoconjugation, including colchicine,^[9] mitomycin,^[10] podophyllotoxin,^[11] rapamycin,^[12] isophosphoramide mustards,^[13] or taxol,^[14] such targets remain beyond chemoenzymatic strategies. Recent studies on OleD, the oleandomycin (**1**) GT from *Streptomyces antibioticus* (Scheme 1a), revealed an enhanced triple mutant (A242V/S132F/P67T, referred to herein as ASP) that displayed marked improvement in proficiency and substrate promiscuity.^[4] To probe the synthetic utility of this enhanced catalyst and expand upon previous reports of acceptor promiscuity for wild-type (WT) OleD,^[15] we report a comparison of the aglycon specificities of the WT and ASP OleD variants toward 137 drug-like acceptors. This study highlights the ability of OleD variants to glucosylate a total of 71 diverse acceptors and to catalyze iterative glycosylation with numerous substrates, and it establishes OleD as the first multifunctional GT capable of generating *O*-, *S*- and *N*-glycosides.

Enzymes for the study were overproduced as N-terminal His-tag-fusions in *E. coli* and purified to homogeneity as previously described.^[4,5] Each member of the acceptor library (3–139) was first assessed as a substrate for enzyme-catalyzed



Scheme 1. a) Natural reaction catalyzed by WT OleD. b) General reaction for probing aglycon promiscuity in vitro against a panel of 137 library members; X = OH, SH, NH₂, or NHR.

glucosylation with UDP-glucose (UDP-Glc) as the donor and either WT or ASP OleD as catalyst (Scheme 1b). The library included molecules with diverse nucleophiles and representative alkaloid, β -lactam, enediyne, non-ribosomal peptide, polyketide, and steroid natural products. Each member was assayed using a single “universal” assay condition (50 mM Tris HCl (pH 8.0), 5 mM MgCl₂, 0.5 μ g μ L⁻¹ purified enzyme, 2.5 mM UDP-Glc, 1 mM aglycon, 25°C, 16 h). Glycoside production was determined by HPLC and LC-MS, and control reactions lacking either enzyme or UDP-glucose confirmed that products were dependent upon both enzyme and donor.

From this first-pass analysis, enzyme-catalyzed glucosylation of 71 of the 137 library members (52%) was observed (Figure 1). ASP provided higher conversion with 56 of the 71 substrates and, in 10 cases (**14**, **18**, **47**, **53**, **66**, **67**, **70–73**), product was observed only with ASP. In contrast, only polyene **57** was a unique substrate of WT OleD. Notably, of the 71 new substrates, 4 (**6**, **20**, **22**, **42**) and 21 (**13**, **19**, **23**, **26**, **29**, **33**, **34**, **37**, **43–45**, **47**, **48**, **50**, **52**, **53**, **55**, **56**, **61**, **63**, **72**) library members exclusively contained either *S*- or *N*-based nucleophiles, respectively. While the first-pass LC-MS analysis could not distinguish regio- or stereoselectivity, it is important to note that among the subgroup of library members containing multiple nucleophiles (34 members), 20 led to a single, chromatographically distinct, monoglucosylated product. Perhaps most surprising was that 13 substrates (**3**, **4**, **6**, **9**, **18–21**, **23**, **26**, **29**, **33**, **35**) led to products with masses corresponding to the addition of multiple glucose moieties, and within this group, 10 (**3**, **6**, **19–21**, **23**, **26**, **29**, **33**, **35**) contained only a single heteroatom, implicating disaccharide formation

[*] R. W. Gantt, R. D. Goff, G. J. Williams, Prof. J. S. Thorson
UW National Cooperative Drug Discovery Group
Laboratory for Biosynthetic Chemistry, School of Pharmacy
University of Wisconsin-Madison
777 Highland Avenue, Madison, WI 53705 (USA)
Fax: (+1) 608-262-5345
E-mail: jsthorson@pharmacy.wisc.edu

[**] The authors thank the University of Wisconsin-Madison School of Pharmacy Analytical Facility for analytical support. This research was supported in part by National Institutes of Health Grants AI52218 and U19 CA113297.

Supporting information for this article is available on the WWW under <http://dx.doi.org/10.1002/ange.200803508>.





Figure 1. a) Percent conversion of each library member with both WT and ASP OleD. Members are listed in descending order of ASP conversion with numbering corresponding to the structures listed in (b). b) Structures of the corresponding library members. Compounds leading to trace products (**58–73**, > 5% conversion) or no conversion (**74–139**) are listed in the Supporting Information.

through iterative glycosylation. To confirm *O*-, *S*- and *N*-glucoside formation and iterative glycosylation, and deter-

mine anomeric stereoselectivity, a select set of OleD-catalyzed reactions with simple aromatic model acceptors phenol

(**8**), thiophenol (**6**), and aniline (**34**) were studied in depth. NMR characterization of products isolated from large-scale reactions was consistent with the β -*O*-, *S*- and *N*-glucosides (**140–143**, Scheme 2, $J = 6.7$, 7.8 , and 9.6 Hz for H1, respectively). Iterative glycosylation of model acceptor **6** was also



Scheme 2. Products isolated from large scale enzymatic reactions of ASP OleD with a) phenol (**8**), b) thiophenol (**6**), and c) aniline (**34**).

determined to be both regio- and stereoselective to provide the 2'-*O*-(β -D-glucosyl)-glucoside **143** ($J = 7.8$ and 9.8 Hz for H1 and H1', respectively). Interestingly, while the kinetic parameters for all three model substrates fell within the range of previously reported values (Table 1 in the Supporting Information),^[4,5] the ranked order of WT OleD catalytic efficiency (k_{cat}/K_m ; thiophenol > phenol $\approx$ aniline) differed from that for ASP (phenol > aniline > thiophenol). Consistent with the enhanced proficiency of ASP,^[4] this mutant was improved 25-, 5-, and 4-fold, respectively, toward phenol (**8**), aniline (**34**), and thiophenol (**6**).

In terms of potential for combinatorial applications, this study revealed WT OleD and ASP to glucosylate a diverse range of “drug-like” scaffolds including anthraquinones, indolocarbozoles, polyenes, cardenolides, steroids, macro- lides, β -lactams, and enediynes (Figure 1). Of particular note is that library members (or closely related compounds) are clinical analgesic (**28**), gout (**55**), congestive heart failure (**24**), hormone replacement (**18**), antifungal (**57**), antiparasitic (**43**), antibacterial (**36**, **53**, **63**, **69**), and anticancer (**14**, **17**, **32**, **38**, **62**) agents.^[16] Although there exist a few reported natural or engineered “bifunctional” GTs, capable of forming two types of glycosidic bonds (*O/N*-, *O/S*-, or *O/C*-),^[17–20] this is the first example of a GT capable of catalyzing *O*-, *S*-, and *N*-glycosidic bond formation. Moreover, putative ASP-catalyzed glycosidic bond formation was observed with aliphatic alcohols, aliphatic thiols, *N*-substituted anilines, oximes, hydrazines, hydrazides, *N*-hydroxyamides, *O*-substituted oxy- amines, and carboxylic acids (Figure 1), the heteroatom nucleophiles of which represent a pK_a range of 4–14.^[21] Although glycosides of oximes,^[22] hydrazines,^[23] hydrazides,^[24] *N*-hydroxyamides,^[25] and *O*-substituted oxyamines^[9,26] have been chemically synthesized, to the best of our knowledge, this is the first enzyme-catalyzed route. While a few naturally occurring iterative GTs also exist,^[8] this is the first report of

OleD-catalyzed iterative glycosylation. Cumulatively, the scaffold, nucleophile, and iterative adaptability of OleD clearly sets the stage for further engineering of custom GT catalysts for many applications.^[4,5,27]

In the context of GT promiscuity, the role of OleD in macrolide self-resistance (**1**, **2**, Scheme 1 a) may require this enzyme to uniquely adapt to accommodate alternative acceptors. Yet, even with library members containing multiple nucleophiles, the majority of reactions studied were remarkably regio- and stereoselective. Although other reports have highlighted moderate promiscuity of natural product GTs,^[6,10,11,28–30] the underlying structural basis for maintaining specificity with variant acceptors is not well understood. Studies designed to understand the promiscuity of other enzyme classes implicate drastic enzyme conformational changes,^[31] voluminous active sites,^[32] or similar conformational binding of unrelated compounds within the active site^[33] as potential contributors to promiscuity. Consistent with this, substrate modelling of the promiscuous GT VinC suggested that gross molecular size and hydrogen-bonding interactions play significant roles.^[29] Future structural studies of enhanced OleD variants bound to diverse substrates are critical to extend our currently limited understanding of GT specificity and catalysis. However, given the high conservation of the GT-B structural fold among natural product GTs,^[34] including OleD,^[35] other examples of drastically promiscuous GTs are likely to emerge.

Received: July 18, 2008

Published online: October 16, 2008

Keywords: carbohydrates · enzymes · glycosides · glycosylation · natural products

- a) A. C. Weymouth-Wilson, *Nat. Prod. Rep.* **1997**, *14*, 99–110; b) J. S. Thorson, T. J. Hosted, Jr., J. Jiang, J. B. Biggins, J. Ahlert, *Curr. Org. Chem.* **2001**, *5*, 139–167; c) V. Křen, T. Řezanka, *FEMS Microbiol. Rev.* **2008**, *32*, 858–889.
- a) J. A. Salas, C. Méndez, *Trends Microbiol.* **2007**, *15*, 219–232; b) C. J. Thibodeaux, C. E. Melançon, H. Liu, *Nature* **2007**, *446*, 1008–1016; c) S. Blanchard, J. S. Thorson, *Curr. Opin. Chem. Biol.* **2006**, *10*, 263–271.
- a) B. R. Griffith, J. M. Langenhan, J. S. Thorson, *Curr. Opin. Biotechnol.* **2005**, *16*, 622–630; b) J. M. Langenhan, B. R. Griffith, J. S. Thorson, *J. Nat. Prod.* **2005**, *68*, 1696–1711.
- a) G. J. Williams, C. Zhang, J. S. Thorson, *Nat. Chem. Biol.* **2007**, *3*, 657–662; b) G. J. Williams, J. S. Thorson, *Nat. Protoc.* **2008**, *3*, 357–362.
- G. J. Williams, R. D. Goff, C. Zhang, J. S. Thorson, *Chem. Biol.* **2008**, *15*, 393–401.
- X. Fu, C. Albermann, J. Jiang, J. Liao, C. Zhang, J. S. Thorson, *Nat. Biotechnol.* **2003**, *21*, 1467–1469.
- C. Zhang, B. R. Griffith, Q. Fu, C. Albermann, X. Fu, I. Lee, L. Li, J. S. Thorson, *Science* **2006**, *313*, 1291–1294.
- C. Zhang, C. Albermann, X. Fu, J. S. Thorson, *J. Am. Chem. Soc.* **2006**, *128*, 16420–16421.
- A. Ahmed, N. R. Peters, M. K. Fitzgerald, J. A. Watson, Jr., F. M. Hoffmann, J. S. Thorson, *J. Am. Chem. Soc.* **2006**, *128*, 14224–14225.
- A. Ghiorghis, A. Talebian, R. Clarke, *Cancer Chemother. Pharmacol.* **1992**, *29*, 290–296.
- T. F. Imbert, *Biochimie* **1998**, *80*, 207–222.

- [12] M. Abel, R. Szweda, D. Trepanier, R. W. Yatscoff, R. T. Foster, U.S. Patent No. US 7,160,867, **2007**.
- [13] M. Veyhl, et al., *Proc. Natl. Acad. Sci. USA* **1998**, *95*, 2914–2919, see Supporting Information.
- [14] D. Liu, S. Sinchaikul, P. V. G. Reddy, M. Chang, S. Chen, *Bioorg. Med. Chem. Lett.* **2007**, *17*, 617–620.
- [15] M. Yang, M. R. Proctor, D. N. Bolam, J. C. Errey, R. A. Field, H. J. Gilbert, B. G. Davis, *J. Am. Chem. Soc.* **2005**, *127*, 9336–9337.
- [16] *Drug Information Handbook*, 16th ed. (Eds.: C. F. Lacy, L. L. Armstrong, M. P. Goldman, L. L. Lance), Lexi-Comp, Hudson, **2008**, pp. 22–30, 112–114, 314–315, 381–382, 427–430, 580–585, 723–725, 1151–1152, 1350–1351, 1609–1610, 1065–1067.
- [17] C. Loutre, D. P. Dixon, M. Brazier, M. Slater, D. J. Cole, R. Edwards, *Plant J.* **2003**, *34*, 485–493.
- [18] M. Brazier-Hicks, W. A. Offen, M. C. Gershater, T. J. Revett, E. Lim, D. J. Bowles, G. J. Davies, R. Edwards, *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 20238–20243.
- [19] A. Patana, M. Kurkela, M. Finel, A. Goldman, *Protein Eng. Des. Sel.* **2008**, *21*, 537–543.
- [20] C. Dürr, D. Hoffmeister, S. Wohlert, K. Ichinose, M. Weber, U. Von Mulert, J. S. Thorson, A. Bechthold, *Angew. Chem.* **2004**, *116*, 3022–3025; *Angew. Chem. Int. Ed.* **2004**, *43*, 2962–2965.
- [21] Data available at <http://www.chem.wisc.edu/areas/reich/pkatable/>.
- [22] E. C. Rodriguez, L. A. Marcaurelle, C. R. Bertozzi, *J. Org. Chem.* **1998**, *63*, 7134–7135.
- [23] J. P. Holland, et al., *Inorg. Chem.* **2007**, *46*, 465–485, see Supporting Information.
- [24] Y. Takeda, *Carbohydr. Res.* **1979**, *77*, 9–23.
- [25] M. Thomas, J. Gesson, S. Papot, *J. Org. Chem.* **2007**, *72*, 4262–4264.
- [26] a) F. Peri, *Minirev. Med. Chem.* **2003**, *3*, 658–665; b) J. M. Langenhan, J. S. Thorson, *Curr. Org. Syn.* **2005**, *2*, 59–81; c) F. Nicotra, L. Cipolla, F. Peri, B. La Ferla, C. Redaelli, *Adv. Carb. Chem. Biochem.* **2008**, *61*, 363–410.
- [27] a) A. Aharoni, K. Thieme, C. P. C. Chiu, S. Buchini, L. L. Lairson, H. Chen, N. C. J. Strynadka, W. W. Wakarchuk, S. G. Withers, *Nat. Methods* **2006**, *3*, 609–614; b) B. M. Persson, M. M. Palcic, *Anal. Biochem.* **2008**, *378*, 1–7.
- [28] C. L. Freel Meyers, M. Oberthür, J. W. Anderson, D. Kahne, C. T. Walsh, *Biochemistry* **2003**, *42*, 4179–4189.
- [29] A. Minami, R. Uchida, T. Eguchi, K. Kakinuma, *J. Am. Chem. Soc.* **2005**, *127*, 6148–6149.
- [30] C. Zhang, et al., *ChemBioChem* **2006**, *7*, 795–804, see Supporting Information.
- [31] M. Ekroos, T. Sjögren, *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 13682–13687.
- [32] T. Kuzuyama, J. P. Noel, S. B. Richard, *Nature* **2005**, *435*, 983–987.
- [33] C. Liu, B. E. Deavours, S. B. Richard, J. Ferrer, J. W. Blount, K. Huhman, R. A. Dixon, J. P. Noel, *Plant Cell* **2006**, *18*, 3656–3669.
- [34] L. L. Lairson, B. Henrissat, G. J. Davies, S. G. Withers, *Annu. Rev. Biochem.* **2008**, *77*, 521–555.
- [35] D. N. Bolam, et al., *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 5336–5341, see Supporting Information.